Cosmo (SWX:COPN) has reported its H1 2026 results with trailing 12 month revenue of €102.7 million and a loss of €6.4 million, translating to an EPS loss of €0.38, while the current share price sits at CHF63.6. The company has seen revenue move from €130.6 million in H2 2024 to €52.5 million in H2 2025 on a half year basis, with EPS shifting from €3.73 to a loss of €0.10 over the same periods. This sets up a results season in which investors are weighing forecasted growth against pressure on margins and the path back to profitability.
See our full analysis for Cosmo.With the latest numbers on the table, the next step is to see how these results line up with the widely followed growth, profitability, and risk narratives that have built up around Cosmo over the past year.
See what the community is saying about Cosmo
Losses Narrow On A Half Year Basis
- Cosmo moved from net income of €62.0 million in H2 2024 to losses of €2.0 million in H1 2025 and €1.6 million in H2 2025, with basic EPS shifting from earnings of €3.73 to small losses of €0.13 and €0.10 over these half year periods.
- Consensus narrative points to multiple growth drivers in AI diagnostics and specialty drugs. However, these recent half year losses show that earnings are still adjusting to that shift, so investors are watching how quickly products like GI Genius and Winlevi translate into more stable profits.
Trailing 12 Month Loss Of €6.4 Million
- On a trailing 12 month view into H1 2026, Cosmo reported revenue of €102.7 million and a net loss of €6.4 million, compared with a trailing period that included €182.3 million of revenue and €60.0 million of net income in 2025.
- Bulls argue that forecasts for about 30.3% annual revenue growth and 48.6% annual earnings growth justify looking past the current loss. However, the shift from trailing net income of €60.0 million to a €6.4 million loss shows that the bullish growth story is starting from a weaker profit base than those forecasts alone might suggest.
- The five year trend of losses being reduced by roughly 16.9% per year supports the idea of progress, while the latest trailing loss highlights that the path is not yet complete.
- With earnings today at a loss of €3.6 million in the forecast framework, bullish expectations for much higher future earnings rest on a sizeable swing from the current reported position.
Mixed Valuation Signals At CHF63.60
- At a share price of CHF63.60, Cosmo trades on a P/S of 10.8x versus 3.9x for the wider European Pharmaceuticals industry and 21x for its peer group, while the DCF fair value reference of CHF1,079.08 and analyst price target of CHF122.14 both sit well above the current price level.
- Critics highlight that the 3.07% dividend is not covered by earnings or free cash flow, so the combination of an uncovered payout and current unprofitability gives cautious investors reasons to question how long this dividend policy can be maintained even if revenue and earnings forecasts are achieved.
- The current loss position on both the half year and trailing 12 month views contrasts with the positive yield, so some investors may treat the dividend as less dependable than that percentage figure suggests.
- The tension between a P/S that looks high versus the broader industry but lower versus peers, and a dividend that lacks coverage, leaves readers focusing closely on how quickly reported earnings move back into positive territory.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cosmo on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
With sentiment split between Cosmo's recent losses and its longer term growth ambitions, this is a moment to look at the data yourself and move quickly to an informed view. To weigh both the concerns and the potential rewards side by side, start by reviewing the 2 key rewards and 1 important warning sign.
See What Else Is Out There Beyond Cosmo
Cosmo is wrestling with recent losses, an uncovered 3.07% dividend and a higher P/S than the broader European Pharmaceuticals industry, which together raise questions about risk and income reliability.
If this mix of losses and dividend uncertainty feels uncomfortable, now is a good time to check a list of 293 resilient stocks with low risk scores that aims to prioritise more resilient profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com